Companies › Polaris Group
1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Gastroenterology, Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADI-PEG 20 Argininosuccinate synthase 1 (ASS1) depletion via pegylated arginine deiminase | ASS1 | Phase 3 | Hepatocellular Carcinoma; Glioblastoma Multiforme (GBM); Nonalcoholic Steatohepatitis (NASH); Prostate Cancer | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04587830 | ADI-PEG 20 | Phase 2 | Glioblastoma Multiforme (GBM) | Oncology | Feb 2027 |
| NCT06085729 | ADI-PEG 20 | Phase 1 | Prostate Cancer | Oncology | Sep 2027 |
| NCT05842512 | ADI-PEG 20 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | Gastroenterology | Dec 2027 |
| NCT05317819 | ADI-PEG 20 | Phase 3 | Hepatocellular Carcinoma | Oncology | Sep 2028 |
Cash of $302m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
–
Corcept Therapeutics Colgate Palmolive Puma Biotechnology Phathom Pharmaceuticals LaNova Medicines Zhejiang
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.